Legal Proceedings Initiate Against Abbott Laboratories Over Infant Formula

A significant legal case commenced in Chicago on March 4, targeting global healthcare company Abbott Laboratories. The core of the litigation involves allegations from multiple families who claim that a specific cow’s milk-based infant formula produced by the company caused severe health complications in premature babies. This trial forms one part of a much broader wave of lawsuits currently facing the entire infant nutrition industry.

Industry-Wide Legal Scrutiny Intensifies

The litigation landscape for formula manufacturers is expanding rapidly. Across the United States, nearly 1,000 cases are currently pending against various companies in the sector. Specifically, more than 700 individual proceedings are active against Abbott and other manufacturers in federal courts located in Illinois alone.

The lawsuits center on a connection between the formula and necrotizing enterocolitis (NEC), a serious and often life-threatening intestinal condition predominantly affecting preterm infants. This is not the first legal challenge for Abbott; courts rendered decisions in several cases against both Abbott and its competitor Mead Johnson in 2024. Those prior judgments are now moving through the appeals process. The new proceeding in Cook County is expected to provide crucial guidance for the legal strategy surrounding hundreds of similar pending claims.

Concurrent Safety and Contamination Concerns

Alongside the courtroom battles, the infant formula industry is confronting increased scrutiny from independent research organizations. In March 2026, Consumer Reports published test findings that detected the presence of lead, arsenic, and PFAS (per- and polyfluoroalkyl substances) in numerous products from several different manufacturers.

Should investors sell immediately? Or is it worth buying Abbott Laboratories?

Abbott Laboratories has contested these findings. The company maintains that its products comply with all existing regulatory limits for heavy metals. In response to growing concerns, the U.S. Food and Drug Administration (FDA) enhanced its oversight in 2025 through an initiative called “Operation Stork Speed.” The agency announced plans for stricter safety standards and expanded testing protocols for infant formula.

Regulatory Pressure Mounts Globally

The sector now operates under significantly heightened regulatory observation worldwide. Internationally, criminal investigations targeting some of Abbott’s competitors have introduced further market uncertainty. These probes have already triggered product recalls and led to intensified controls at manufacturing facilities.

For Abbott, the ongoing Chicago trial represents an additional burden in a market environment already characterized by tension. The outcome of this proceeding is likely to have a substantial influence on the company’s approach to managing the several hundred other lawsuits it faces, potentially shaping its legal and corporate strategy for years to come.